Monitoring Response and Setting Expectations: A Long-Term Partnership With Patients

Managing patient expectations on JAK-inhibitor therapy for alopecia areata requires clinicians to establish a long-term frame from the very first prescription conversation.

Even when a JAK inhibitor successfully halts immune-mediated follicular destruction— which it may do relatively early in the treatment course-the biological process of visible hair regrowth lags significantly behind disease suppression. Hair cycling and regeneration from a follicle that has been dormant for months or years takes time that cannot be accelerated pharmacologically, and patients who do not understand this distinction are at risk of concluding, prematurely and incorrectly, that their medication is not working. Discussing this timeline clearly and proactively-framing it as established biology rather than clinical uncertainty-allows patients to remain committed to therapy through the months before visible results emerge. The clinical mantra of "underpromise, overdeliver" is particularly well suited to AA management, where patients who are warned that regrowth will take time are often pleasantly surprised by how much they ultimately recover.

In practice, this means dermatologists should explicitly defer any outcome-oriented assessment of hair regrowth for at least 6 months from the start of therapy, with many practitioners extending that window to 9 or even 12 months for patients who want to give the medication a full opportunity to demonstrate its effect. The follow-up schedule reflects this long arc: an initial visit around the 1-month mark to review laboratory results required for JAK-inhibitor safety monitoring, a follow-up at approximately 3 to 4 months, and then visits every 3 to 6 months depending on stability and response. Patients who are pending prior authorization or appeal can often be bridged with samples to prevent a gap in care. Clinical trial data substantiate the value of patience: SALT scores in pivotal AA trials continued to decrease meaning hair coverage continued to improve through 18 to 24 months of treatment, well beyond the timepoint at which many patients might otherwise have abandoned therapy out of discouragement.

In this closing segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, describes his follow-up protocol for patients on JAK inhibitors and explains the biology behind the extended therapeutic timeline in terms he uses with his own patients. Aboul-Fettouh also reflects on the broader significance of having disease-modifying options available for AA patients who, just a few years ago, had none-

-and closes with direct encouragement for community

dermatologists preparing to write their first JAK-inhibitor prescription for this indication, emphasizing that the resources, manufacturer support, and clinical rewards are all in place to make that first prescription worth writing.